Topical Oxytetracycline-Polymyxin—Further Observations

Publisher Website
Google Scholar
Abstract
In 1959, I reported on the use of oxytetracycline hydrochloride (Terramycin)-polymyxin B sulfate powder* in 5,691 patients without significant allergic reactions.1 Since that report, I have had the opportunity to use this preparation on more than 5,500 additional patients with dermatological problems similar to those in the previous report. Summary Together with 5,691 cases in a previous report, the present series of 5,500 cases brings to over 11,000 the total number of patients treated by me with a powder containing 3.31% oxytetracycline hydrochloride and 0.144% polymyxin B sulfate in U.S.P. lactose. In not a single case has there been observed a definite instance of eczematous dermatitis from the topical use of oxytetracycline hydrochloride or of polymyxin B sulfate. Conclusion With the powder preparation studied, allergic eczematous dermatitis from the topical use of oxytetracycline hydrochloride or polymyxin B sulfate would seem to be virtually nonexistent. Sherwood W. Barefoot, M.D., 1030

This publication has 0 references indexed in Scilit: